

**perindopril arginine 5mg and indapamide 1.25mg tablets
(Coversyl Arginine Plus®) (No: 474/08)**

Servier Laboratories Ltd

Product Update

09 May 2008

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

perindopril arginine 5mg and indapamide 1.25mg tablet (Coversyl Arginine Plus®) is accepted for use in NHS Scotland for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on perindopril alone and for whom this combination is an appropriate choice of therapy.

The 5mg perindopril arginine in this formulation is equivalent in terms of the content of perindopril base to the 4mg perindopril tert-butylamine contained in the formulation previously available.

After review of a full submission, SMC issued advice on 8th September 2003 that the previously available formulation of perindopril, indapamide (Coversyl Plus®) was recommended for general use within NHS Scotland. It produces a modest reduction in blood pressure in patients with essential hypertension uncontrolled by perindopril alone.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 11 March 2008.

**Chairman,
Scottish Medicines Consortium**